Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells +…(TAIL) | Phase 1 | terminated | May 23, 2012 | Baylor College of Medicine | not stated | Not stated |
| NCT01510756 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Jan 16, 2012 | Thomas Kipps | slow enrollment | Enrollment / accrual |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01739491 | A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino… | — | withdrawn | Dec 3, 2012 | Janssen Pharmaceutica | The study is cancelled. FDA Circular 2013-004 mandates that PMSs like this are not required | Other (stated, no rule matched) |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | Phase 1 | withdrawn | Dec 20, 2007 | University of Arkansas | no accrual | Enrollment / accrual |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT00587847 | Campath Maintenance in Chronic Lymphocytic Leukemia | N/A | terminated | Jan 8, 2008 | Northwell Health | Insufficient recruitment. | Enrollment / accrual |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell… | Phase 2 | withdrawn | Dec 20, 2010 | UNC Lineberger Comprehensive Cancer Center | No patients enrolled and funding has been withdrawn. | Enrollment / accrual |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in…(LUCID) | Phase 2 | terminated | Oct 23, 2006 | Biogen | not stated | Not stated |
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR)… | Phase 2 | terminated | Dec 3, 2008 | Biogen | not stated | Not stated |
| NCT01625741 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients…(HYDRIC) | Phase 2 | terminated | Jun 21, 2012 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Stopped by Principal Investigator decision | Investigator |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2010 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute…(ALLPhi) | Phase 1 / Phase 2 | terminated | May 20, 2009 | Rony Schaffel | The study was terminated due to excessive toxicity and low compliance to the protocol scheme. | Safety / toxicity |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | Phase 2 | terminated | Dec 19, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | Phase 2 | terminated | Oct 13, 2008 | M.D. Anderson Cancer Center | Lack of accrual. | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01271283 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | Phase 2 | withdrawn | Jan 6, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study… | Phase 1 / Phase 2 | terminated | Jul 19, 2011 | University of Ulm | Insufficient recruitment | Enrollment / accrual |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic… | Phase 1 | terminated | Dec 24, 2004 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01463852 | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation… | Early Phase 1 | terminated | Nov 2, 2011 | Dartmouth-Hitchcock Medical Center | Enrollment underperformance. | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Enrollment terminated in 2005 to focus on Phase 3 study enrollment. | Enrollment / accrual |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple… | Phase 2 | withdrawn | Mar 10, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Sep 27, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Oct 8, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab… | Phase 3 | withdrawn | Apr 27, 2006 | GlaxoSmithKline | This study has been cancelled prior to enrollment | Enrollment / accrual |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | Phase 2 | withdrawn | Jul 19, 2007 | Meir Medical Center | We found out that there is another study on the same issue | Other (stated, no rule matched) |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients… | Phase 4 | withdrawn | Oct 20, 2005 | Novartis | not stated | Not stated |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed… | Phase 2 | withdrawn | Jun 30, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | not stated | Not stated |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Feb 4, 2010 | University of Arkansas | Slow accrual; PI left primary institution | Investigator |
| NCT00210340 | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis | Phase 1 | withdrawn | Sep 21, 2005 | International Extranodal Lymphoma Study Group (IELSG) | lack of accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 8, 2016source: clinicaltrials